The Experts below are selected from a list of 1118259 Experts worldwide ranked by ideXlab platform

Karl Heinz Schwalbe - One of the best experts on this subject based on the ideXlab platform.

Jerold R Gold - One of the best experts on this subject based on the ideXlab platform.

  • psychotherapy integration and alliance use of cognitive behavioral techniques within a short term psychodynamic Treatment Model
    Journal of Psychotherapy Integration, 2013
    Co-Authors: Rachel E Goldman, Mark J Hilsenroth, Jesse Owen, Jerold R Gold
    Abstract:

    This study examined the relationship between Psychodynamic-Interpersonal (PI) and Cognitive-Behavioral (CB) techniques used in a Short-Term Psychodynamic Psychotherapy with the therapeutic alliance early in Treatment. Ninety-one outpatient participants rated their alliances, and independent videotape ratings of technique were made. Our findings did not support the primary hypothesis of a relationship between technique integration and overall patient-rated alliance. However, our findings did demonstrate a significant association between the integration of PI and CB techniques with the two alliance subscales Goals & Task Agreement and Confident Collaboration. In addition, specific PI and CB techniques were significantly correlated with higher patient alliance scores on these two subscales. Psychodynamic therapists who are more collaborative in identifying specific goals and explicitly defining the focus of the Treatment with their patients, as well as providing a clear rationale for their Model, may facilitate a stronger therapeutic alliance specific to patient confidence in, and agreement with, the Treatment process.

Kenneth D. Somers - One of the best experts on this subject based on the ideXlab platform.

  • Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a Treatment Model of mouse prostate cancer
    Cancer Immunology Immunotherapy, 2003
    Co-Authors: Richard P. Ciavarra, Roy R. Brown, Daniel A. Holterman, Marianne Garrett, William F. Glass, George L. Wright, Paul F. Schellhammer, Kenneth D. Somers
    Abstract:

    We have previously reported that Fms-like tyrosine kinase-3 ligand (flt3-L) induced tumor stabilization and regression of palpable ectopic prostate tumors (TRAMP-C1). Although some mice remained "tumor free" for several months following termination of therapy, tumors invariably reappeared and grew progressively in all animals. The lack of a curative response suggests that TRAMP-C1 tumors may inhibit the development of a flt3-L-induced anti-tumor immune response. Consistent with this view, we demonstrate herein that TRAMP-C1 tumors isolated from flt3-L treated animals contained a marked dendritic cell (DC) infiltrate that was temporally correlated with tumor regression. However, tumor-associated DCs, especially in a flt3-L setting, progressively lost MHC class II antigen expression during tumor growth. Treatment with the DC maturation factor trimeric CD40 ligand (CD40-L) either alone or in combination with fl3-L neither prevented loss of DC class II antigens nor disease relapse. Because loss of class II antigens would prevent CD4+ helper T (Th) cell development, we treated tumor-bearing mice with agonistic anti-4-1BB antibody (Ab), which can promote cytotoxic T lymphocyte (CTL) development independent of Th cell function. However, anti-4-1BB Ab alone did not alter TRAMP-C1 growth kinetics, and, when used in combination, was no more effective than flt3-L alone. The inability of the 4-1BB co-stimulatory signal to promote tumor regression may have been related to two additional features of TRAMP-C1 tumors. First, tumor-associated T cells, but not splenic T cells from tumor-bearing animals, were profoundly deficient in expression of CD3-epsilon (CD3ε) and T cell receptor-beta chain (TCRβ). Second, CTLs required 24 h to efficiently kill TRAMP-C1 target cells even after up-regulation of MHC class I antigens by interferon-γ. This rate of tumor cell destruction by CTLs may not be sufficient to prevent tumor progression. Taken together, these data reveal several important immunosuppressive characteristics of the prostate tumor microenvironment (TME) that immunotherapeutic interventions must first overcome to achieve long-term cures. These data also highlight the importance of utilizing Treatment versus vaccination Models in the evaluation of immunotherapeutic modalities.

Çağdaş Saz - One of the best experts on this subject based on the ideXlab platform.

  • Cost-effectiveness of boron (B) removal from irrigation water: an economic water Treatment Model (EWTM) for farmers to prevent boron toxicity
    Environmental Science and Pollution Research, 2019
    Co-Authors: Onur Can Türker, Anıl Yakar, Cengiz Türe, Çağdaş Saz
    Abstract:

    Protection of water sources which are used for irrigation has raised great interest in the last years among the environmental strategists due to potential water scarcity worldwide. Excessive boron (B) in irrigation water poses crucial environmental problems in the agricultural zones and it leads to toxicity symptoms in crops, as well as human beings. In the present research, economic water Treatment Models consist of dried common wetland plants ( Lemna gibba , Phragmites australis , and Typha latifolia ) and Lemna gibba accumulation was tested and assessed to create a simple, cost-effective, and eco-friendly method for B removal from irrigation water. Significant amount of B was removed from irrigation water samples by EWTMs and B concentrations decreased below

Dwight Reynolds - One of the best experts on this subject based on the ideXlab platform.

  • A New Paradigm of Cardiovascular Risk Factor Modification
    Vascular health and risk management, 2005
    Co-Authors: Muhammad Firdaus, Jeffrey M. Asbury, Dwight Reynolds
    Abstract:

    Atherosclerotic cardiovascular diseases (CVDs) are the leading cause of death and disability in the United States. While multiple studies have demonstrated that modification of atherosclerotic cardiovascular risk factors (CVRFs) significantly reduces morbidity and mortality rates, clinical control of CVDs and CVRFs remains poor. By 2010, the American Heart Association seeks to reduce coronary heart disease, stroke, and risk by 25%. To meet this goal, clinical practitioners must establish new Treatment paradigms for CVDs and CVRFs. This paper discusses one such Treatment Model--a comprehensive atherosclerosis program run by physician extenders (under physician supervision), which incorporates evidence-based CVD and CVRF interventions to achieve Treatment goals.